Q2 2026 Nektar Therapeutics Earnings Call Transcript

Aug 13, 2026 / 09:00 PM GMT

Release Date Price: €64.84 (+0.46%)

Transcript 10-Q8-K

Key Points

Positve

Initiated the global Phase 3 Zenith AD program for Respeg in atopic dermatitis, with first data expected in mid-2028 and BLA submission planned for 2029.
Received FDA alignment for a single registrational Phase 3 study in alopecia areata, with a broad patient population and potential for a broad label.
Strong financial position with over $1 billion in cash and investments, extending cash runway into Q3 2028, past initial Phase 3 data readouts.
Market research with 151 physicians showed high enthusiasm for Respeg's novel mechanism, quarterly dosing, and safety profile, supporting first-line and later-line use.
Positive Phase 2b data showed deepening responses over time, including up to a five-fold increase in EZ100 rates during maintenance, and no increased infection or conjunctivitis risk.
Respeg's Treg agonist mechanism works upstream of multiple inflammatory pathways, potentially addressing comorbidities like asthma and allergic rhinitis, with secondary endpoints included in Phase 3 trials.

Negative

Phase 3 data for atopic dermatitis is not expected until mid-2028, and BLA submission not until 2029, indicating a long timeline before potential commercialization.
Alopecia areata Phase 3 study initiation is planned for early 2027, with data expected in second-half 2029, delaying potential market entry.
The company faces ongoing litigation, with a jury trial scheduled for September 8th, and management declined to comment on potential outcomes, creating uncertainty.
R&D expenses are expected to increase quarterly in 2026 as Phase 3 studies progress, potentially impacting near-term profitability.
The company's net loss for Q2 2026 was $40.6 million, and full-year revenue is only expected to be $40-45 million, indicating continued reliance on cash reserves.
Competitive landscape in alopecia areata includes other non-JAK treatments, and while management downplays recent data, it may still pose a threat to Respeg's market positioning.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NKTR.OQ - Nektar Therapeutics
Q2 2026 Nektar Therapeutics Earnings Call
Aug 13, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and thank you for standing by. Welcome to the Nectar Therapeutics Second Quarter 2026 Financial Results Conference Call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question-and-answer session.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Vivian Wu from Nectar Investor Relations to kick things off. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Crystal, and good afternoon, everyone.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.